Sponsor or institution

Clinical trials and research at Otsuka Pharmaceutical Development & Commercialization, Inc.

• 12Clinical trials
• 21Countries

Newest trials

All recruiting trials (12)

• Long-term safety and tolerability of SEP-363856 in adults with generalized anxiety disorder

  In adults with generalized anxiety disorder, this Phase 3 open-label extension tests whether continuing SEP-363856 at 50 mg or 75 mg daily for 26 weeks is safe, tolerable, and possibly helpful.

  Recruiting at 2 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Jacksonville, Florida and 1 other locations · NCT07786454

• Fixed-dose SEP-363856 vs placebo for adults with generalized anxiety disorder

  This trial tests whether a fixed 75 mg/day dose of SEP-363856 helps adults with generalized anxiety disorder more than placebo over 8 weeks.

  Recruiting at 11 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Redlands, California and 10 other locations · NCT07767903

• Centanafadine in adults with ADHD and emotional dysregulation

  This study tests centanafadine XR once daily to see if it helps adults with ADHD who also have emotional dysregulation.

  Recruiting at 16 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Gainesville, Florida and 15 other locations · NCT07759154

• Fixed-dose SEP-363856 for Generalized Anxiety Disorder

  A large, global study will test whether daily doses of SEP-363856 (50 mg or 75 mg) help adults with generalized anxiety disorder more than a placebo over 8 weeks.

  Recruiting at 17 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Tucson, Arizona and 16 other locations · NCT07759128

• How Repinatrabit is processed in adults with liver or kidney impairment versus normal function

  This study tests how Repinatrabit is handled by the body in adults with moderate liver impairment or severe kidney impairment compared to adults with normal liver function.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Miami, Florida · NCT07713758

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Test of NDI-5001 in adult men with X-linked nephrogenic diabetes insipidus

  This trial tests whether NDI-5001 is safe and well taken up in the body when taken as capsules by adult men with X-linked nephrogenic diabetes insipidus.

  Recruiting at 2 sites Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Santa Ana, California and 2 other locations · NCT07525960

• Repinatrabit's effects on common medicines like birth control, metformin, carbamazepine, rosuvastatin, and methotrexate

  This trial will test whether repinatrabit changes how common medicines—ethinyl estradiol/norethindrone (birth control), metformin, carbamazepine, rosuvastatin, and methotrexate—act in healthy adults.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Melbourne, Victoria · NCT07446400

• Quabodepistat-containing regimens for drug-resistant pulmonary tuberculosis

  This will test whether quabodepistat combined with other TB drugs can shorten treatment and be safer for adults and teens with rifampicin-resistant or multidrug-resistant pulmonary TB.

  Recruiting at 33 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Beijing, Beijing Municipality and 41 other locations · NCT07209761

• JNT-517 treatment for adults with phenylketonuria (PKU)

  This study will test whether taking JNT-517 pills twice daily lowers high blood phenylalanine and is safe for adults with PKU.

  Recruiting at 26 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Los Angeles, California and 25 other locations · NCT06971731

• Long-term JNT-517 treatment for people with phenylketonuria

  This trial tests the long-term safety of JNT-517 in children and adults with PKU, including people who previously took JNT-517 and those who are new to the drug.

  Recruiting at 12 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Gainesville, Florida and 11 other locations · NCT06628128

• Evaluating the safety of tolvaptan in children with ARPKD

  This study is testing if the medication tolvaptan is safe for children with autosomal recessive polycystic kidney disease (ARPKD) over an 18-month period.

  Recruiting at 13 sites Phase 3 Otsuka Pharmaceutical Development & Commercialization, Inc. · Washington D.C., District of Columbia and 22 other locations · NCT04782258

Quick answers

How many clinical trials run by Otsuka Pharmaceutical Development & Commercialization, Inc. are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in United States (9 trials), Australia (4 trials), Japan (2 trials), Germany (2 trials), Poland (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 8, Phase 1: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →